Heather Bresch, CEO of embattled drug maker Mylan, testified before a House panel last week that one of the main reasons the company had to hike up the prices on its signature EpiPens from $100 to ...

Mylan, the embattled maker of allergy treatment EpiPen, lowered its 2016 earnings guidance Friday after it agreed to pay $465 million in a settlement with federal regulators over its pricing ...

Drugmaker Mylan said Monday that it will offer a generic version of the life-saving allergy treatment EpiPen for half the list price of the brand-name treatment after it became the center of a ...

Mylan NV was hit Monday with a lawsuit alleging the drug company overcharged EpiPen patients as part of an illegal scheme to secure sales. The lawsuit, which is seeking class-action status, is the ...

You can add Mylan Laboratories to the list of drug makers boosting prices by big amounts. Over the past six months, the company, which is one of the world’s largest purveyors of generic ...

Drug maker Mylan Pharmaceuticals, under fire from the public and Congress over the soaring price of its anaphylaxis treatment, will launch a generic version of the EpiPen auto-injector at a list ...

For years, Mylan Pharmaceuticals has been selling the devices to schools at a discounted price, giving them a break from rising costs. But the program also prohibited schools from buying ...

A group of disgruntled Mylan investors launched a campaign late Tuesday to block the re-election of six directors over their exorbitant—and increasing—compensation. That’s according to a ...

The EpiPen eventually became Mylan’s single most important product, accounting for $1 billion of its $7.7 billion in sales in 2014 and of its $9.4 billion in sales in 2015, according to ...

Pharmaceutical giant Mylan has raised the price of the EpiPen more than 500% over the last six years, leaving parents shocked and scrambling to buy the injection device for children with life ...

Shares of Mylan were up 6% in trading on Thursday after the drugmaker restarted production of hydroxychloroquine-sulfate tablets, which are being considered as a possible treatment for people with ...

new video loaded: Mylan Chief on the $600 EpiPen Heather Bresch, chief executive of Mylan, discusses the controversy surrounding the recent 400-percent increase in her company’s life-saving ...